OliX PharmaceuticalsInc - Asset Resilience Ratio

Latest as of December 2025: 64.57%

OliX PharmaceuticalsInc (226950) has an Asset Resilience Ratio of 64.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩126.15 Billion

≈ $85.49 Million USD Cash + Short-term Investments

Total Assets

₩195.37 Billion

≈ $132.40 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how OliX PharmaceuticalsInc's Asset Resilience Ratio has changed over time. Check OliX PharmaceuticalsInc (226950) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down OliX PharmaceuticalsInc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OliX PharmaceuticalsInc stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩126.15 Billion	64.57%
Total Liquid Assets	₩126.15 Billion	64.57%

Asset Resilience Insights

Very High Liquidity: OliX PharmaceuticalsInc maintains exceptional liquid asset reserves at 64.57% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

OliX PharmaceuticalsInc Industry Peers by Asset Resilience Ratio

Compare OliX PharmaceuticalsInc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for OliX PharmaceuticalsInc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for OliX PharmaceuticalsInc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	64.57%	₩126.15 Billion ≈ $85.49 Million	₩195.37 Billion ≈ $132.40 Million	+52.61pp
2024-12-31	11.96%	₩8.52 Billion ≈ $5.78 Million	₩71.25 Billion ≈ $48.28 Million	-1.59pp
2023-12-31	13.55%	₩13.93 Billion ≈ $9.44 Million	₩102.83 Billion ≈ $69.68 Million	-33.09pp
2022-12-31	46.64%	₩61.87 Billion ≈ $41.93 Million	₩132.65 Billion ≈ $89.90 Million	-10.77pp
2021-12-31	57.41%	₩49.76 Billion ≈ $33.72 Million	₩86.67 Billion ≈ $58.74 Million	-29.27pp
2020-12-31	86.68%	₩68.11 Billion ≈ $46.16 Million	₩78.58 Billion ≈ $53.25 Million	+42.54pp
2019-12-31	44.14%	₩19.95 Billion ≈ $13.52 Million	₩45.21 Billion ≈ $30.64 Million	-7.65pp
2018-12-31	51.79%	₩28.81 Billion ≈ $19.53 Million	₩55.64 Billion ≈ $37.70 Million	-0.51pp
2017-12-31	52.30%	₩11.32 Billion ≈ $7.67 Million	₩21.64 Billion ≈ $14.67 Million	-10.30pp
2016-12-31	62.60%	₩9.48 Billion ≈ $6.43 Million	₩15.15 Billion ≈ $10.27 Million	--

pp = percentage points

About OliX PharmaceuticalsInc

KQ:226950 Korea Biotechnology

Market Cap

$1.29 Billion

₩1.91 Trillion KRW

Market Cap Rank

#7683 Global

#192 in Korea

Share Price

₩94800.00

Change (1 day)

+5.92%

52-Week Range

₩47250.00 - ₩207000.00

All Time High

₩207000.00